openPR Logo
Press release

Metachromatic Leukodystrophy Pipeline Therapeutics Review 2018

Metachromatic Leukodystrophy Pipeline Therapeutics Review

Metachromatic leukodystrophy (MLD) is an inherited disease that causes fat accumulation in cells. The disease affects the nervous system which produces myelin sheath for insulation and protection of nerves. The fatty deposition, called sulfatides in nerve cells causes the destruction of white matter, which is formed by myelin sheath. It further deteriorates the cognitive functioning of nerves such as an ability to walk, loss of sensation (also known as peripheral neuropathy), seizure, incontinence, inability to speak, paralysis, hearing loss, and blindness. The late infantile form is the common form of metachromatic leukodystrophy that affects in the second year of life and causes loss of speech, gait disturbances and weakness in children. In patients with metachromatic leukodystrophy, the mutation in ARSA gene causes the deficiency of the enzyme, arylsulfatase A, which helps in breakdown of sulfatides. This leads to accumulation of sulfatides in nerve cells. The Shenzhen University is in the process of developing transduced CD34+ hematopoietic stem cell for the treatment of metachromatic leukodystrophy. The University of Minnesota is in the process of developing stem cell transplantation for the treatment of metachromatic leukodystrophy. Some of the companies having the pipeline of metachromatic leukodystrophy include Shire plc, GlaxoSmithKline plc, Zymenex A/S and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/mld-therapeutics-pipeline-analysis/report-sample

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/mld-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Metachromatic Leukodystrophy Pipeline Therapeutics Review 2018 here

News-ID: 974205 • Views:

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments
Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it

All 5 Releases


More Releases for Metachromatic

Global Interbody Cages Market to Progress at a Substantial CAGR by 2026, Asserts …
DelveInsight's 'Interbody Cages Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Interbody Cages and the historical and forecasted Interbody Cages market trends, globally, which comprises of North America, Europe, APAC, and RoW. Some of the Interbody Cages Companies are • Aurora Spine, Inc. • B. Braun Melsungen AG • Benvenue Medical, Inc. • Ulrich Medicals USA • Prodorth • Orthofix International N.V. • Medtronic, plc • Zimmer Biomet, Inc. • NuVasive, Inc. • Johnson &
Angioedema Market, Epidemiology, Treatment, Pipeline, Drugs, Companies and Compe …
Angioedema is swelling underneath the skin. It's usually a reaction to a trigger, such as a medicine or something you're allergic to. It is not normally serious, but it can be a recurring problem for some people and can very occasionally be life-threatening if it affects breathing. DelveInsight's "Angioedema Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angioedema, historical and forecasted epidemiology as well as the
Gene Therapy Therapeutics-Pipeline Analysis 2018, Clinical Trials & Results | No …
Gene therapy is a technique that involves treatment or prevention of a disease by using genes. Several methodologies are being used in the gene therapy that involve replacing the mutated gene, inactivating or silencing the mutated gene, and introducing a new gene into the body. Download the sample report at: https://www.pharmaproff.com/request-sample/1184 This results in the formation of beneficial protein. A gene cannot be directly delivered into the human body, because of
GervanoRA Announced the Release of Opportunity Assessment Report Titled “Metac …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Metachromatic Leukodystrophy Pipeline Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics, and Pipeline Analysis H2 2018. GervanoRA’s pipeline analysis and opportunity assessment report “Metachromatic Leukodystrophy: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis, H2 2018” analyzed and assessed Metachromatic Leukodystrophy pipeline molecules for the
Metabolic Disorders Therapeutics Market to Perceive Substantial Growth During 20 …
Metabolic disorders usually occur due to disruption of the normal processes of the body. These disorders can be hereditary or acquired and the symptoms differ from person to person. Some metabolic disorders cause mild symptoms that can be managed with slight medication and lifestyle changes, whereas few can cause life-threatening symptoms, such as breathing problems, seizure, and organ failure. The treatment for inherited metabolic disorders requires long-term nutritional supplementation and
Metachromatic Leukodystrophy Pharmaceutical and Healthcare Analysis Information
Pune, India, 18th December 2017: WiseGuyReports announced addition of new report, titled “Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2017”. Summary Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms include vision problems leading to blindness, personality changes, and motor disturbances such as clumsiness, muscle weakness (hypotonia), rigidity, inability to coordinate movement (ataxia), and/or muscle spasms especially of the neck, spine, arms, and legs.